Microsatellite Instability, Epstein–Barr Virus, and Programmed Cell Death Ligand 1 as Predictive Markers for Immunotherapy in Gastric Cancer

Hung Yuan Yu, Chung Pin Li, Yi Hsiang Huang, Shao Jung Hsu, Yen Po Wang, Yun Cheng Hsieh, Wen Liang Fang, Kuo Hung Huang, Anna Fen Yau Li, Rheun Chuan Lee, Kang Lung Lee, Yuan Hung Wu, I. Chun Lai, Wan Chin Yang, Yi Ping Hung, Yu Chao Wang, Shu Hui Chen, Ming Huang Chen*, Yee Chao

*此作品的通信作者

研究成果: Article同行評審

3 引文 斯高帕斯(Scopus)

摘要

Immunotherapy benefits selected cases of gastric cancer (GC), but the correlation between biomarkers and prognosis is still unclear. Fifty-two patients with GC who underwent immunother-apy were enrolled from June 2016 to December 2020. Their clinical features and biomarkers—mi-crosatellite instability-high (MSI-H), programmed cell death ligand 1 (PD-L1) combined positive score (CPS), and Epstein–Barr encoding region (EBER)—were analyzed. Eight patients had MSI-H, five patients had EBER, 29 patients had CPS ≥ 1, and 20 patients had no biomarker. The overall response rates (ORRs) of the MSI-H, EBER, PD-L1 CPS ≥ 1, and all-negative group were 75%, 60%, 44.8%, and 15%, respectively. Compared with that of the all-negative group, progression-free survival (PFS) was better in the MSI-H (p = 0.018), CPS ≥ 5 (p = 0.012), and CPS ≥ 10 (p = 0.006) groups, but not in the EBER (p = 0.2) and CPS ≥ 1 groups (p = 0.35). Ten patients had combined biomarkers, CPS ≥ 1 with either MSI-H or EBER. The ORRs were 66.7% for CPS ≥ 1 and MSI-H and 75% for CPS ≥ 1 and EBER. PFS was better in patients with combined biomarkers (p = 0.01). MSI-H, EBER, and CPS are useful biomarkers for predicting the efficacy of immunotherapy.

原文English
文章編號218
期刊Cancers
14
發行號1
DOIs
出版狀態Published - 1 1月 2022

指紋

深入研究「Microsatellite Instability, Epstein–Barr Virus, and Programmed Cell Death Ligand 1 as Predictive Markers for Immunotherapy in Gastric Cancer」主題。共同形成了獨特的指紋。

引用此